{
  "id": 1304,
  "text": "There was no evidence to suggest that the effect of NACT on survival varied across groups of patients defined by age, stage, histology, grade or performance status.It should be noted that (1) there was a greater proportion of stage IB-II patients than in the first comparison, (2) intra-arterial chemotherapy and pelvic radiotherapy were used in the NACT plus surgery arm in one trial1138, (3) almost all patients received pelvic radiotherapy in two trials1125,1126, and (4) pelvic radiotherapy was given to approximately $3 0 \\%$ of patients in another two trials1138,1139.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: There was no evidence to suggest that the effect of NACT on survival varied across groups of patients defined by age, stage, histology, grade or performance status.It should be noted that (1) there was a greater proportion of stage IB-II patients than in the first comparison, (2) intra-arterial chemotherapy and pelvic radiotherapy were used in the NACT plus surgery arm in one trial1138, (3) almost\n\n<question>: ",
  "ChatGPT_response_0": "根据现有数据显示，针对使用新辅助化疗的癌症治疗患者群体，并没有证据表明不同年龄、病期、组织学、分级或表现状态的患者在生存率方面有显著差异。在一些相关研究中发现，针对不同特征的患者群体，新辅助化疗的疗效并没有表现出明显的差异。值得注意的是一些研究中使用了不同方式的治疗，例如内动脉化疗和盆腔放疗等可能对结果产生影响。需要综合考虑患者的具体情况和治疗方案，以做出更好的治疗决策。如果您有更多关于特定患者群体的疗效数据需求，请咨询您的医疗专家以获取个性化的建议。",
  "query": "针对癌症治疗过程中使用新辅助化疗的患者群体，是否有相关疗效数据显示不同年龄、病期、组织学、分级或表现状态的患者在生存率方面有所差异？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 针对癌症治疗过程中使用新辅助化疗的患者群体，是否有相关疗效数据显示不同年龄、病期、组织学、分级或表现状态的患者在生存率方面有所差异？\n\n<reference text>: There was no evidence to suggest that the effect of NACT on survival varied across groups of patients defined by age, stage, histology, grade or performance status.It should be noted that (1) there was a greater proportion of stage IB-II patients than in the first comparison, (2) intra-arterial chemotherapy and pelvic radiotherapy were used in the NACT plus surgery arm in one trial1138, (3) almost all patients received pelvic radiotherapy in two trials1125,1126, and (4) pelvic radiotherapy was given to approximately $3 0 \\%$ of patients in another two trials1138,1139.\n\n<reply>: ",
  "response": "根据现有数据显示，针对使用新辅助化疗的癌症治疗患者群体，并没有证据表明不同年龄、病期、组织学、分级或表现状态的患者在生存率方面有显著差异。在一些相关研究中发现，针对不同特征的患者群体，新辅助化疗的疗效并没有表现出明显的差异。值得注意的是一些研究中使用了不同方式的治疗，例如内动脉化疗和盆腔放疗等可能对结果产生影响。需要综合考虑患者的具体情况和治疗方案，以做出更好的治疗决策。如果您有更多关于特定患者群体的疗效数据需求，请咨询您的医疗专家以获取个性化的建议。"
}